Search results
-
ELCC 2025 – BioNTech impresses in small-cell lung
… 42% – lower than the 73% reported from the same study at ESMO 2023. Still, the result is in line with the 40% ORR …
- 03/28/2025 - 15:08 -
AACR 2025 preview – distressed biotechs seek redemption
… Ph1 low-dose irinotecan combo Had monoRx data at ESMO 2023 D3S-001 KRAS G12C inhibitor D3 Bio …
- 03/28/2025 - 08:55 -
Imfinzi puts its flag on the Matterhorn
… already read out positively for pCR, with data presented at ESMO 2023, but the trial remained blinded for EFS, and it's … PD-L1 at a level of at least 1%. It will be noted that ESMO 2023 showed Matterhorn's pCR benefit to be strongest in …
- 03/11/2025 - 15:11 -
Bristol exits KRAS G12D
… Hengrui) Inhibitor Lacklustre ph1 data at ESMO 2023 GFH375 Verastem/GenFleet Inhibitor …
- 03/06/2025 - 13:30 -
ASCO-GU – Pfizer looks for bigger bladder cancer invasion
… urothelial cancer + Keytruda, vs chemo Data at ESMO 2023: 53% reduction in risk of death; FDA approved Dec …
- 02/12/2025 - 15:51 -
Two more reasons for GSK to be wary of Tim-3
… as sabestomig had posted mediocre efficacy data at ESMO 2023 . Its discontinuation means that GSK's cobolimab …
- 02/06/2025 - 15:35 -
AstraZeneca doubles down on GPC3
… which had yielded phase 1 safety and biomarker data at ESMO 2023. The company didn’t give a reason for its …
- 02/05/2025 - 14:05 -
Mersana shows that B7-H4 expression matters
… basis of a 29% ORR among 28 TNBC patients, reported at ESMO 2023 . However, while this Chinese trial enrolled …
- 02/05/2025 - 10:14 -
Triple meeting 2024 – Zai Lab impresses in small cell
… Presentation venue Triple meeting 2024 ESMO 2023 ASCO 2024 ORR 74% (14/19)* 40% …
- 10/29/2024 - 13:27 -
Merck and Daiichi look beyond small cell with ifinatamab
… Safety, antitumour activity Data at WCLC & ESMO 2023: ORR 52% in SCLC; 21% in ESCC; 25% in mCRPC; 31% …
- 10/24/2024 - 13:51
